Compugroup Medspadr 1 Stock Current Asset
| COPA Stock | EUR 20.80 0.20 0.97% |
COMPUGROUP MEDSPADR 1 fundamentals help investors to digest information that contributes to COMPUGROUP MEDSPADR's financial success or failures. It also enables traders to predict the movement of COMPUGROUP Stock. The fundamental analysis module provides a way to measure COMPUGROUP MEDSPADR's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to COMPUGROUP MEDSPADR stock.
COMPUGROUP |
COMPUGROUP MEDSPADR 1 Company Current Asset Analysis
COMPUGROUP MEDSPADR's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
In accordance with the recently published financial statements, COMPUGROUP MEDSPADR 1 has a Current Asset of 0.0. This is 100.0% lower than that of the Healthcare sector and about the same as Health Information Services (which currently averages 0.0) industry. The current asset for all Germany stocks is 100.0% higher than that of the company.
Did you try this?
Run ETFs Now
ETFsFind actively traded Exchange Traded Funds (ETF) from around the world |
| All Next | Launch Module |
COMPUGROUP Fundamentals
| Return On Equity | 0.11 | |||
| Return On Asset | 0.031 | |||
| Profit Margin | 0.06 % | |||
| Operating Margin | 0.08 % | |||
| Shares Outstanding | 52.23 M | |||
| Price To Earning | 53.50 X | |||
| Revenue | 1.13 B | |||
| Gross Profit | 373.55 M | |||
| EBITDA | 149.63 M | |||
| Net Income | 72.32 M | |||
| Cash And Equivalents | 91.45 M | |||
| Cash Per Share | 1.73 X | |||
| Total Debt | 685.04 M | |||
| Debt To Equity | 1.19 % | |||
| Current Ratio | 0.91 X | |||
| Book Value Per Share | 12.98 X | |||
| Cash Flow From Operations | 165.54 M | |||
| Earnings Per Share | 1.37 X | |||
| Number Of Employees | 8.83 K | |||
| Beta | 1.02 | |||
| Market Capitalization | 2.72 B | |||
| Z Score | 1.8 | |||
| Annual Yield | 0.01 % | |||
| Last Dividend Paid | 0.5 |
About COMPUGROUP MEDSPADR Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze COMPUGROUP MEDSPADR 1's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of COMPUGROUP MEDSPADR using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of COMPUGROUP MEDSPADR 1 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in COMPUGROUP Stock
COMPUGROUP MEDSPADR financial ratios help investors to determine whether COMPUGROUP Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in COMPUGROUP with respect to the benefits of owning COMPUGROUP MEDSPADR security.